Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO)
strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC).
Hence, this is a combination study of nivolumab and ipilimumab in Epstein-Barr virus (EBV)
driven nasopharyngeal carcinoma.